Development of Specific Fluorogenic Substrates for Human β-N-Acetyl-D-hexosaminidase A for Cell-Based Assays
- 1 June 2020
- journal article
- research article
- Published by Pharmaceutical Society of Japan in CHEMICAL & PHARMACEUTICAL BULLETIN
- Vol. 68 (6), 526-533
- https://doi.org/10.1248/cpb.c20-00069
Abstract
Inhibitors of human β-N-acetyl-D-hexosaminidase (hHEX) A and human O-GlcNAcase (hOGA) reportedly play roles in multiple diseases, suggesting their potential for pharmacological chaperone (PC) therapy of Sandhoff disease (SD) and Tay–Sachs disease (TSD), as lysosomal storage diseases, and Alzheimer’s disease and progressive supranuclear palsy, respectively. In particular, hHEXA inhibitors as PCs have been shown to successfully enhance hHEXA levels, leading to the chronic form of SD and TSD. In the diagnosis of enzyme deficiencies in SD and TSD, artificial hHEXA substrates based on 4-methylumbelliferone as a fluorophore are available and generally used; however, they do not have sufficient performance to screen for potential inhibitors for a PC therapy from compound libraries. Further, there are currently few fluorogenic substrates for hHEXA suitable for such requirements and there are no substrates ideal for cell-based inhibitor screening. Here, we clarified the difference in enzyme active site structure between hHEXA and hOGA from their tertiary structures. To develop lysosome-localized hHEXA-specific fluorogenic substrates based on the difference in their active site structures, our developed quinone methide cleavage substrate design platform was applied for the molecular design of substrates. Thereafter, we synthesized via the shortest route and evaluated novel three-color fluorogenic substrates for hHEXA that exhibited excellent specificity and sensitivity in three human cell lines. The designed substrates represent the first-in-a class of new substrates that can be utilized to screen hHEXA inhibitors in adherent human cultured cells.Keywords
This publication has 24 references indexed in Scilit:
- Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for TauopathiesJournal of Medicinal Chemistry, 2019
- Versican and Tumor-Associated Macrophages Promotes Tumor Progression and Metastasis in Canine and Murine Models of Breast CarcinomaFrontiers in Oncology, 2019
- Potent GH20 N-Acetyl-β-d-hexosaminidase Inhibitors: N-Substituted 3-acetamido-4-amino-5-hydroxymethyl-cyclopentanediolsMolecules, 2018
- Sphingolipid lysosomal storage disordersNature, 2014
- O‐GlcNAcase is essential for embryonic development and maintenance of genomic stabilityAging Cell, 2012
- Cell-Penetrant, Nanomolar O-GlcNAcase Inhibitors Selective against Lysosomal HexosaminidasesCell Chemical Biology, 2010
- Isoforms of human O-GlcNAcase show distinct catalytic efficienciesBiochemistry (Moscow), 2010
- High-Throughput Screening for Human Lysosomal β-N-Acetyl Hexosaminidase Inhibitors Acting as Pharmacological ChaperonesCell Chemical Biology, 2007
- Crystal Structure of Human β-Hexosaminidase B: Understanding the Molecular Basis of Sandhoff and Tay–Sachs DiseaseJournal of Molecular Biology, 2003
- Direct Determination of the Substrate Specificity of the α-Active Site in Heterodimeric β-Hexosaminidase ABiochemistry, 1996